Cardiovascular (CV) safety concerns are a significant source of drug development attrition in the pharmaceutical industry today.
Integrated and Translational Nonclinical In Vivo Cardiovascular Risk Assessment: Gaps and Opportunities
Regulatory Toxicology and Pharmacology, 2013